Ublituximab for treating relapsing multiple sclerosis

  • Technology appraisal guidance
  • TA1025
  • Published: 

History

Documents created during the development process.

Final draft guidance

Notes

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6350